FDA approved Braftovi, Erbitux, and mFOLFOX6 for BRAF V600E mutation-positive metastatic colorectal cancer. BREAKWATER trial showed a 61% objective response rate for the treatment group versus 40% for ...
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
Hosted on MSN26d
Pfizer gets FDA accelerated approval for BraftoviThe agency approved the medication, also known as encorafenib, to be used in combination with cetuximab, also known as Erbitux, and mFOLFOX6 chemotherapy for the treatment of patients with mCRC ...
The combination resulted in a median overall survival (OS) of 9 months for the combination therapy compared to 5.4 months for chemotherapy plus Erbitux, the current standard-of-care treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback